Background The survival benefit of first-line epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) therapy in super-elderly patients with advanced non-small cell lung …

7561 Background: First line treatment by gefitinib for NSCLC patients with EGFR mutations
has been validated by us (NEJ 002 Study) and WJTOG3405. In these studies, patients with …

Purpose The efficacy of gefitinib [an epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor] in elderly patients with non-small cell lung cancer (NSCLC) and EGFR …

Introduction: Recent studies have demonstrated that first-line treatment with gefitinib, an
epidermal growth factor receptor (EFGR)–targeted tyrosine kinase inhibitor, is significantly …

Internal Medicine Vol.49 Page 1 103 □ ORIGINAL ARTICLE □ Efficacy of Gefitinib for Elderly
Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor …

7563 Background: The first-line treatment with gefitinib has been established as a standard
of care for advanced NSCLC patients with EGFR mutation by previous studies including …

e18094 Background: Potential treatment strategies for elderly patients (pts) with advanced
non-small cell lung cancer (NSCLC) have not been well investigated. Gefitinib has …

The clinical efficacy and outcomes of gefitinib therapy as a first-line treatment for elderly
patients with non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor …

The efficacy of epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) in
elderly patients with non‑small‑cell lung cancer (NSCLC) remains uncertain. This …

Introduction Feasibility of gefitinib therapy in elderly patients with non–small-cell lung cancer
is uncertain. This phase II study aimed to investigate the efficacy and usefulness of gefitinib …